Amgen Stock Sees Institutional Changes Amid Strong Earnings

Amgen Inc.'s stock has been on the move lately, and several institutions have made notable adjustments to their positions. According to a recent 13F filing with the Securities & Exchange Commission, Commerce Bank reduced its stake in Amgen by 1.3% in the second quarter. The bank sold 3,459 shares of AMGN stock during this period, leaving it with 256,448 shares worth $92.865 million.

Several other large investors also made changes to their holdings in Amgen during the same quarter. Brighton Jones LLC increased its position by 23.5%, while Sivia Capital Partners and Schnieders Capital Management grew their stakes by 10.6% and 29.3%, respectively. Main Street Financial Solutions and Ieq Capital LLC also boosted their investments, with increases of 11.3% and 5.1%, respectively.

Amgen's quarterly earnings data released on August 4th showed the company beating expectations, with revenue rising year-over-year and earnings per share topping consensus estimates. The medical research company reported $6.29 in EPS for Q2, exceeding analyst forecasts of $5.62. Amgen's second-quarter results were a significant factor contributing to its strong stock performance.